About

Our Mission

2N Pharma was founded in 2019 to build on a decade of research undertaken by our co-founder and CSO Dr. John Nieland and his associates. While the challenge ahead is immense, our aim is clear: we want to cure ALS.

We make this bold statement well knowing that brilliant scientists have had very limited success in developing disease modifying drugs, despite many decades of research. But we believe our novel approach to treating neurological disorders will be the departure from conventional neuroscience that is required to finally make significant progress towards a cure for ALS.

2N Pharma at BII

2N Pharma has joined the BioInnovation Institute (BII) in Copenhagen, Denmark, an international initiative by the Novo Nordisk Foundation to support life science startups in bringing interdisciplinary ideas to life and research to market.

Support embraces every phase of a life-science start-up and is giving us access to high-level mentoring and international networks that will accelerate our speed to market of therapeutic drugs.

Board of Directors

Alex Leech

Chair

Alex was the founding CEO of Alchemab Therapeutics and raised a £60m ($82m) Series A in 2021. He is a serial biotech CEO having led Creabilis, a leading European dermatology company, until its acquisition by Sienna Biopharmaceuticals Inc. in December 2016 and was CEO of Zarodex Therapeutics and Camphos Therapeutics. Prior to Creabilis, he led operations at US-based pain company Solace Pharmaceuticals Inc. Alex gained his R&D experience at Pfizer and is a Venture Partner with SV Health Investors.

John Kemp, PhD

Director

John is  currently the CSO of Syndesi Therapeutics. Former roles include Head of Neuroscience Discovery at Janssen, Belgium and CEO of Evotec Neurosciences, which was spun-out from Evotec and raised a €25m Series A in 2004. Before joining Evotec, John was SVP and Head of CNS Research at Roche and he also held senior research positions in Neuroscience R&D at Merck Sharpe and Dohme. John has published over 140 peer reviewed articles, was an original member of ISI’s Most Highly Cited Researcher Database and has an h-index of 74.

Preben Bruun-Nyzell

Director

Preben is 2N Pharma’s co-founder and CEO and brings broad business and finance experience from an international career spanning nine countries over 25 years. He is co-founder of clinical stage vaccine company 2A Pharma, chairman of Apoglyx, a Swedish biotech focused on aquaporins and earlier in his career worked for Roche in Basel and PwC in London. Previously, Preben was CFO of a company in the Middle East with 1,200 employees and sales of $1bn.

John Nieland, PhD

Director

John is 2N Pharma’s co-founder and CSO and brings broad management experience and an in-depth research background. He was previously director of research at Medigene AG and is co-founder of the clinical stage vaccine company 2A Pharma and two other biotech companies. In addition to his duties at 2N Pharma, John is Associate Professor and Head of the Molecular Pharmacology Department at Aalborg University, Denmark.

Giles Dudley, PhD

Board Observer

Giles is a Portfolio Manager at the BioInnovation Institute in Copenhagen and non-voting board observer. He has more than 10 years experience with fundraising, business development, market due diligence and IP development in biotech startups. Giles has a PhD in virology and previously worked with Sunergos Innovations, Edinburgh Bioquarter and several seed stage healthcare companies.

Team Members

Preben Bruun-Nyzell

CEO and Co-Founder

Preben is 2N Pharma’s co-founder and CEO and brings broad business and finance experience from an international career spanning nine countries over 25 years. He is co-founder of clinical stage vaccine company 2A Pharma, chairman of Apoglyx, a Swedish biotech focused on aquaporins and earlier in his career worked for Roche in Basel and PwC in London. Previously, Preben was CFO of a company in the Middle East with 1,200 employees and sales of $1bn.

John Nieland, PhD

CSO and Co-Founder

John is 2N Pharma’s co-founder and CSO and brings broad management experience and an in-depth research background. He was previously director of research at Medigene AG and is co-founder of the clinical stage vaccine company 2A Pharma and two other biotech companies. In addition to his duties at 2N Pharma, John is Associate Professor and Head of the Molecular Pharmacology Department at Aalborg University, Denmark.

Anne Skøttrup Mørkholt, PhD

Project Manager

Anne completed her doctorate at the Laboratory of Metabolism Modifying Medicine, Aalborg University with research into the connection between dysfunction of the lipid metabolism and CNS diseases, including multiple sclerosis and depression.

Steinunn Sara Helgudóttir, Project Manager

Steinunn Sara Helgudóttir, PhD

Project Manager

Steinunn completed her doctorate at the Neurobiology Research and Drug Delivery  Group at Aalborg University with research into targeted drug delivery through the blood-brain barrier. 

Lisa Juul Routhe, PhD

Project Manager

Lisa completed her doctorate at the Laboratory of Neurobiology Group at Aalborg University with research into neuroinflammation and iron handling in diseases with brain iron overload, such as haemorrhagic stroke and chronic neurodegenerative diseases.

Nicole Overmars

Communications Manager

Nicole is responsible for 2N Pharma’s external communication, including our social media presence. She has experience from previous roles in marketing and public relations

Pam Huntjens

Ass. Scientist

Pam is a medical student at Aalborg University and works part-time as a research assistant.

Collaborators & Advisors

Thomas Brimert, PhD

Medicinal Chemistry Advisor

Dr. Brimert received his PhD in organic chemistry from the Royal Institute of Technology in Stockholm. During his 11 years at AstraZeneca R&D Lund, he gained considerable medicinal chemistry experience. He has contributed to successfully delivered clinical candidates in kinase, protease and receptor projects within the respiratory & inflammation therapy area.

During his post-doc with Prof. Jan Becher at the University of Odense in Denmark, he developed new synthetic methods to supramolecular building blocks. Thomas is co-author of 8 scientific publications and 8 patents.

Michael Sloth Trabjerg, MD, PhD

Scientific Advisor

Dr. Trabjerg is a Medical Doctor and completed his PhD at the Laboratory of Metabolism Modifying Medicine, Aalborg University with research into CPT1 as a potential target to restore dysregulated metabolism in neurodegenerative diseases.

Angelique Corthals, MD, PhD

Scientific Advisor

Dr. Corthals is a biomedical researcher who has published on the connection between metabolic dysfunction and neurological disorders. She is Associate Professor at City University of New York and holds a DPhil (PhD) from the University of Oxford.